Skip to Content

Join the 'Osteolytic Bone Lesions of Multiple Myeloma' group to help and get support from people like you.

Osteolytic Bone Lesions of Multiple Myeloma News

Related terms: Multiple Myeloma, Osteolytic Bone Lesions

FDA Approves Xgeva (denosumab) for the Prevention of Skeletal-Related Events in Patients with Multiple Myeloma

Posted 10 Jan 2018 by Drugs.com

THOUSAND OAKS, Calif., Jan. 5, 2018 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Xgeva (denosumab) to expand the currently approved indication for the prevention of skeletal-related events in patients with bone metastases from solid tumors to include patients with ...

CAR T-cell Therapy May Thwart Multiple Myeloma

Posted 5 Jun 2017 by Drugs.com

MONDAY, June 5, 2017 – Genetically tuning a person's own immune cells to target cancer appears to provide long-lasting protection against a blood cancer called multiple myeloma, an early trial from China shows. The treatment, called CAR T-cell therapy, caused 33 out of 35 patients with recurring multiple myeloma to either enter full remission or experience a significant reduction in their ...

Powerful Drug for Advanced Cancers May Need Less Frequent Dosing

Posted 4 Jan 2017 by Drugs.com

WEDNESDAY, Jan. 4, 2017 – Use of a bone cancer drug once every three months, instead of monthly, does not boost the risk of bone problems over two years, a new study finds. That could reduce side effects from the drug, known as zoledronic acid (Zometa), and increase cost savings, the researchers said. The drug is used to treat the spread of breast cancer, prostate cancer and multiple myeloma to ...

Drug Trio Shows Major Promise Against Myeloma

Posted 6 Oct 2016 by Drugs.com

THURSDAY, Oct. 6, 2016 – Adding a newer drug to a standard treatment for advanced cases of multiple myeloma may significantly boost patients' chances of a response and even recovery, a new clinical trial finds. Of patients given the drug, called daratumumab, 43 percent had a complete response – meaning there were no signs of the cancer left. That compared with 19 percent of patients who ...

Superior Results for Myeloma Drug That's Added Earlier in Treatment

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – A recently approved immunotherapy drug for a blood cancer called multiple myeloma can provide even better benefits if patients receive it earlier in their treatment, new clinical trial results show. Darzalex (daratumumab) reduced patients' risk of cancer progression by 70 percent when added to a standard two-drug regimen for people with recurring myeloma, said lead ...

Exercise May Cut Risk of 13 Cancers, Study Suggests

Posted 16 May 2016 by Drugs.com

MONDAY, May 16, 2016 – Exercise may significantly reduce your risk for many types of cancer, including some of the most lethal forms of the disease, a large review suggests. Working out for even a couple of hours a week appears to shrink the risk of breast, colon and lung cancer, said researchers who looked at 1.4 million adults. "Those are three of the four major cancers that affect Americans ...

Experimental Drug Daratumumab for Blood Cancer Shows Promise

Posted 26 Aug 2015 by Drugs.com

WEDNESDAY, Aug. 26, 2015 – An experimental immune-boosting drug shows promise in fighting the blood cancer multiple myeloma, researchers report. Preliminary testing of the drug daratumumab included 72 multiple myeloma patients who had previously received other types of treatment. Their disease had relapsed and no longer responded to treatment. The patients received lower or higher doses of the ...

Ask a Question

Further Information

Related Condition Support Groups

Multiple Myeloma

Related Drug Support Groups

Reclast, Zometa, Xgeva, Aclasta, zoledronic acid, pamidronate, Aredia, denosumab